Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
318 - HI, will the new market created by HC under the MMPR require the Licensed Producers to work with the PAAB?
-
The Healthy Environments and Consumer Safety Branch (HECSB) of Health Canada is responsible for the regulations and associated medicinal marihuana activities. All requests for clarification and complaints surrounding the advertising of medicinal marijuana should be directed to this Branch. As you may know, the primary basis of PAAB review is the Terms of Market Authorization (TMA). We've been informed that as medicinal marihuana is not an authorized health product and there will be no associated health claims, a TMA will not be issued. The PAAB will therefore not be reviewing advertising for medical marijuana. Note that advertisements for medical marijuana will be required to adhere to certain provisions of the Narcotic Control Regulations (NCR) and the Food and Drugs Act (FDA), regardless of the new Marihuana for Medical Purposes Regulations (MMPR).
